NATIONAL INSTITUTES OF HEALTH
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Phase 2
Terminated
- Conditions
- Stage III Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic LeukemiaStage IV Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT00303966
- Locations
- πΊπΈ
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Refractory Multiple MyelomaRefractory Chronic Lymphocytic LeukemiaStage III Multiple MyelomaStage IV Chronic Lymphocytic LeukemiaUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Drug: 17-N-allylamino-17-demethoxygeldanamycin/bortezomib
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2013-03-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00303797
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
Phase 2
Terminated
- Conditions
- Recurrent MelanomaStage IV Melanoma
- Interventions
- Biological: therapeutic autologous lymphocytesProcedure: in vitro-treated peripheral blood stem cell transplantationBiological: gp100 antigenBiological: MART-1 antigenBiological: incomplete Freund's adjuvantBiological: filgrastimBiological: aldesleukin
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00303836
- Locations
- πΊπΈ
National Cancer Institute Surgery Branch, Bethesda, Maryland, United States
Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Phase 1
Completed
- Conditions
- Metastatic MelanomaRenal Cell Cancer
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 138
- Registration Number
- NCT00304460
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
Phase 2
Completed
- Conditions
- High Grade GliomasBrain Tumors
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 43
- Registration Number
- NCT00302159
- Locations
- πΊπΈ
Virginia Commonwealth University, Richmond, Virginia, United States
πΊπΈNational Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
πΊπΈUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors
Phase 2
Completed
- Conditions
- Recurrent Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Borderline Ovarian Surface Epithelial-Stromal TumorStage III Borderline Ovarian Surface Epithelial-Stromal TumorStage IV Ovarian CancerFallopian Tube CarcinomaPrimary Peritoneal CarcinomaRecurrent Ovarian CarcinomaStage III Ovarian Cancer
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00301756
- Locations
- π¨π¦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
π¨π¦Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
π¨π¦University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Phase 1
Terminated
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Blastic Phase Chronic Myelogenous Leukemiade Novo Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00301769
- Locations
- πΊπΈ
M D Anderson Cancer Center, Houston, Texas, United States
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
Phase 1
Completed
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myelomonocytic Leukemia (M4)Adult Acute Promyelocytic Leukemia (M3)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Blastic Phase Chronic Myelogenous LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaSecondary Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00301938
- Locations
- πΊπΈ
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
Phase 2
Completed
- Conditions
- Recurrent Endometrial Carcinoma
- Interventions
- Biological: bevacizumabOther: laboratory biomarker analysis
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT00301964
- Locations
- πΊπΈ
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
Phase 2
Terminated
- Conditions
- Stage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular LymphomaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular Lymphoma
- Interventions
- Biological: oblimersen sodiumBiological: rituximabOther: laboratory biomarker analysis
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 52
- Registration Number
- NCT00301795
- Locations
- πΊπΈ
Cancer and Leukemia Group B, Chicago, Illinois, United States